NEWS
Go back
ARCHIMED Life Science Tools & Services completes carve out of Standard BioTools’ Microfluidics business, now Biomark Scientific
November
10,
2026
Business will operate as Biomark Scientific, a leader in accessible, scalable and automated genomic workflows powered by proprietary microfluidics technology.
The Life Science Tools & Services team of global private equity healthcare specialist ARCHIMED completes the acquisition of Standard BioTools’ Microfluidics business. As part of ARCHIMED, the business enters its next chapter as a standalone business under the name Biomark Scientific.
Biomark Scientific, an innovative microfluidics technology tools provider specializing in high-throughput and multi-assay genomics systems, will offer versatile and scalable genomic profiling on its flagship Biomark™ platform. The next-generation Biomark X9 system is the only automated PCR, qPCR and NGS library prep system on the market, performing simultaneous profiling of multiple types of genomic assay readouts in a single run using patented integrated fluidic circuits (IFCs).
A highly regarded brand in high-throughput genomic workflows serving research institutions, public health laboratories and biobanks, Biomark was previously part of Fluidigm, which was founded in 1999 and renamed Standard BioTools in 2022. As Biomark Scientific, the business will continue to offer its automated bench-top system that can run genomics assays with robustness, speed and precision, driving quality insights for critical, time-sensitive data.
“This is an exciting step forward for our organization, strengthening our ability to serve and support our customers and partners,” says Luke Stewart, newly appointed Chief Commercial Officer of Biomark Scientific. “Together with ARCHIMED, expanding our resources and investing in our expertise reflects our continued commitment to delivering greater value to our customers, with the reliability and quality they depend on. This partnership enables us to confidently move into this next phase while staying true to our foundation of scientific excellence and exceptional service, all in support of advancing genomics and improving public health.”
“With Biomark Scientific’s accelerating position in the clinical research and public health markets, ARCHIMED will support the company in fortifying global growth and launching the business as a primary player in the industry,” says Michael Goetter, Partner at ARCHIMED.
Over the coming months, ARCHIMED Life Science Tools & Services will build the foundations for Biomark Scientific to operate fully on a standalone basis and put a dedicated leadership team in place. Working with the company’s management, ARCHIMED will expand its capabilities, support innovation across genomics, clinical research, and public health, and pursue the firm’s international expansion.
ARCHIMED Life Science Tools & Services sourced the deal directly. The team had identified the sector as a priority through MedSeg, ARCHIMED’s proprietary sector analysis tool covering more than 500 sub-segments of the health industry and had followed Standard BioTools for some time.
“With Biomark Scientific’s accelerating position in the clinical research and public health markets, we are poised to support the company in fortifying global growth and launching the business as a primary player in the industry.”
Michael Goetter, Partner at ARCHIMED
The transaction bears the hallmarks of an ARCHIMED deal: a business sourced directly, a long-standing relationship and a hands-on approach, applied under a demanding timeline. The agreement was signed in a record three weeks, and the acquisition closed within a month. The carve-out demonstrates ARCHIMED ‘s agility, expertise and team collaboration to navigate complex transactions.
ARCHIMED completed the deal through its MED IV fund, which closed on €1.5 billion (three times oversubscribed) last September. All ARCHIMED’s deployed buyout funds from the 2019, 2021, and 2022 vintages are top-quartile performers for their respective vintage years (Preqin 2026).
Past performance is not a guarantee of future results. Capital at risk. For professional investors only.